Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: Results from the BONE study

被引：83

作者：

Recker R.R. ^{[1
]}

Weinstein R.S. ^{[2
]}

Chesnut III C.H. ^{[3
]}

Schimmer R.C. ^{[5
]}

Mahoney P. ^{[4
]}

Hughes C. ^{[3
]}

Bonvoisin B. ^{[6
]}

Meunier P.J. ^{[6
]}

机构：

[1] Creighton Univ. School of Medicine, Creighton University, Omaha, NE

[2] Ctrl. Arkansas Vet. Hlthcare. System, Univ. of Arkansas for Med. Sciences, Little Rock, AR

[3] Osteoporosis Research Group, University of Washington, Seattle, WA

[4] F. Hoffmann-La Roche Ltd., Basel

[5] F. Hoffmann-La Roche Ltd., Welwyn

[6] Hôpital Edouard Herriot, Lyon Cedex

来源：

Osteoporosis International | 2004年 / 15卷 / 3期

关键词：

Histomorphometry; Ibandronate Postmenopausal osteoporosis;

D O I：

10.1007/s00198-003-1530-0

中图分类号：

学科分类号：

摘要：

The bisphosphonate ibandronate, administered either daily or intermittently with an extended between-dose interval of > 2 months, has been shown to reduce significantly the incidence of vertebral fractures, to increase bone mineral density and to reduce levels of biochemical markers of bone turnover in a phase III randomized study in women with postmenopausal osteoporosis (PMO). Bone histomorphometry was performed on a subgroup of women participating in this study in order to assess bone quality and architecture. The patients were randomized to receive one of the following: placebo, continuous oral daily ibandronate (2.5 mg/day) or intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months). Out of the overall study population of 2,946 patients, 110 were randomly assigned to undergo transiliac bone biopsy at either month 22 or month 34 of treatment. The primary safety endpoint was osteoid thickness in trabecular bone, which was measured to exclude treatment-induced bone mineralization defects. Secondary safety endpoints assessed bone volume, bone turnover and micro-architecture. The primary efficacy endpoint was bone mineralizing surface. In all bone biopsy cores, newly formed trabecular bone retained its structure without any signs of woven bone. Marrow fibrosis and signs of cellular toxicity were not observed. Quantitative assessment demonstrated no impairment in mineralization of bone matrix: osteoid thickness tended to be similar or slightly lower in the ibandronate groups versus the placebo group. All secondary safety variables and the bone efficacy parameter were consistent with the production of normal-quality, newly formed bone and a modest reduction in bone turnover with both ibandronate regimens relative to placebo. Long-term treatment with oral ibandronate, even when administered with an extended between-dose interval of > 2 months, produces normal-quality, newly formed bone in women with PMO.

引用

页码：231 / 237

页数：6

共 15 条

[1]

Frost H.M., Tetracycline based histological analysis of bone remodelling, Calcif Tissue Res, 3, pp. 211-237, (1969)

[2]

Delmas P., Recker R., Stakkestad J.A., Et al., Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a unique drug-free interval: Results from a pivotal phase III study, Osteoporos Int, 13, SUPPL. 1, (2002)

[3]

Chavassieux P.M., Arlot M., Meunier P.J., Clinical use of bone biopsy, Osteoporosis, pp. 501-509, (2001)

[4]

Parfitt A.M., Drezner M.K., Glorieux F.H., Et al., Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee, J Bone Miner Res, 2, pp. 595-610, (1987)

[5]

Chavassieux P.M., Arlot M.E., Reda C., Et al., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis, J Clin Invest, 100, pp. 1475-1480, (1997)

[6]

Compston J.E., Vedi S., Stellon A.J., Inter-observer and intra-observer variation in bone histomorphometry, Calcif Tissue Int, 38, pp. 67-70, (1986)

[7]

Chavassieux P.M., Arlot M.E., Meunier P.J., Intersample variation in bone histomorphometry: Comparison between parameter values measured on two contiguous transiliac bone biopsies, Calcif Tissue Int, 37, pp. 345-350, (1985)

[8]

De Vernejoul M.C., Kuntz D., Miravet L., Goutallier D., Ryckewaert A., Bone histomorphometric reproducibility in normal patients, Calcif Tissue Int, 33, pp. 369-374, (1981)

[9]

Bergot C., Laval-Jeantet A.M., Laval-Jeantet M., Etude critique des variations de la mesure de la masse osseuse par biopsie iliaque, Rev Rhum Mal Osteoartic, 45, pp. 317-324, (1978)

[10]

Bravenboer N., Papapoulos S.E., Holzmann P., Hamdy N.A., Netelenbos J.C., Lips P., Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis, Osteoporos Int, 9, pp. 489-493, (1999)

← 1 2 →